RNAC - Cartesian Therapeutics

-

$undefined

N/A

(N/A)

Cartesian Therapeutics NasdaqGM:RNAC Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.

Location: 7495 New Horizon Way, Frederick, MD, 21703, United States | Website: https://www.cartesiantherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

99.92M

Cash

180.4M

Avg Qtr Burn

-7.716M

Short % of Float

27.13%

Insider Ownership

77.58%

Institutional Own.

25.63%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
SEL-212 (Pegadricase) Details
Chronic refractory gout, Arthritis

BLA

Submission

Descartes-08 Details
Myasthenia gravis

Phase 3

Initiation

Descartes-08 Details
Systemic lupus erythematosus

Phase 2

Data readout

Descartes-08 Details
Dermatomyositis

Phase 2

Initiation

Descartes-15 Details
Multiple myeloma

Phase 1

Data readout

SEL-302 (MMA-101 + ImmTOR) Details
Genetic disorder, Methylmalonic acidemia

Failed

Discontinued